| h-debate-c4385a075de | Vesicle Surface Glycan Pattern Recognition | 0.00 | 0.55 | MAPT | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-810c1e5a5ac | Tau-Induced Lipid Membrane Asymmetry Exploitation | 0.00 | 0.55 | MAPT | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-f7e4ecbf7b3 | Tau Conformational State-Specific Nanobody Targeting | 0.00 | 0.55 | MAPT | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-16810224092 | Tau Post-Translational Modification State Targeting | 0.00 | 0.55 | MAPT | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-e52f9e63944 | Chaperone Co-localization Guided Delivery | 0.00 | 0.55 | HSPA1A | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-05624b1daee | Autophagosome Marker Hijacking Strategy | 0.00 | 0.55 | MAP1LC3A | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-075de316a0b | Glial Scar Architecture Manipulation for Functional Compartmentalization | 0.00 | 0.55 | ARAP3, cytoskeletal regulators | proposed | 2026-04-29 | astrocyte-subtypes |
| h-debate-3cd1c9d33ea | Nrf2-NF-κB Oscillatory Circuit Modulation | 0.00 | 0.55 | NFE2L2, NFKB1 | proposed | 2026-04-29 | astrocyte-subtypes |
| h-debate-10f2f867bba | Nascent Transcript Targeting for Real-Time Reprogramming | 0.00 | 0.55 | RNA processing machinery | proposed | 2026-04-29 | astrocyte-subtypes |
| h-debate-cfec1a7354a | Temporal mTOR Modulation for Sequential A1/A2 Switching | 0.00 | 0.55 | MTOR | proposed | 2026-04-29 | astrocyte-subtypes |
| h-debate-49e9c1f5eca | Combinatorial Il-1α/TNFα/C1q Antagonism with Selective Agonism | 0.00 | 0.55 | IL1A, TNF, C1QA, NFE2L2 | proposed | 2026-04-29 | astrocyte-subtypes |
| h-debate-dfbbb1f6b9f | Microglial GLP-1R-Mediated Astrocyte Programming | 0.00 | 0.55 | GLP1R, ARAP3 | proposed | 2026-04-29 | astrocyte-subtypes |
| h-debate-698ff0b1f07 | Age-Stratified Astrocyte Subtype Switching | 0.00 | 0.55 | Multiple age-dependent switches | proposed | 2026-04-29 | astrocyte-subtypes |
| h-debate-68fd2b81578 | Bi-directional Transcytosis Inhibition Strategy | 0.00 | 0.55 | ABCB1 (P-glycoprotein), ABCG2 (BCRP), APP/Aβ | proposed | 2026-04-29 | sda-2026-04-01-gap-008 |
| h-debate-24170addd30 | Intranasal Delivery of BBB-Penetrating Antibody Conjugates | 0.00 | 0.55 | APP/Aβ, olfactory receptor neurons | proposed | 2026-04-29 | sda-2026-04-01-gap-008 |
| h-debate-477286ec859 | Engineered Exosome-Encapsulated Antibody Fragments | 0.00 | 0.55 | APP/Aβ, TFRC, lactoferrin receptor | proposed | 2026-04-29 | sda-2026-04-01-gap-008 |
| h-debate-a513718a3ee | Cell-Penetrating Peptide Conjugated Nanobodies | 0.00 | 0.55 | APP/Aβ oligomers, various CPP sequences | proposed | 2026-04-29 | sda-2026-04-01-gap-008 |
| h-debate-72a94a5767c | LRP1-Mediated Trojan Horse Delivery System | 0.00 | 0.55 | LRP1 (low-density lipoprotein receptor-related protein 1), A | proposed | 2026-04-29 | sda-2026-04-01-gap-008 |
| h-debate-0df96d9a759 | Dual-Targeting BBB Shuttle-Amyloid Antibodies | 0.00 | 0.55 | TFRC (transferrin receptor), APP/Aβ | proposed | 2026-04-29 | sda-2026-04-01-gap-008 |
| h-debate-fcc43254015 | Focused Ultrasound-Enhanced Antibody Delivery | 0.00 | 0.55 | APP/Aβ, tight junction proteins (claudins, occludin) | proposed | 2026-04-29 | sda-2026-04-01-gap-008 |
| h-debate-7a1478ba484 | Peptide Mimetics to Block Domain Interaction | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-010 |
| h-debate-067c9990db5 | Selective APOE4 Degradation and Replacement | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-010 |
| h-debate-083bf9f93d2 | Chaperone-Mediated APOE4 Refolding Therapy | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-010 |
| h-debate-18a83bb5a4e | Small Molecule Domain Disruptors for APOE4 Normalization | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-010 |
| h-debate-b4326ad0de4 | Allosteric Modulators Targeting Lipid Binding Enhancement | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-010 |
| h-debate-c417be99639 | Targeted Cysteine Substitution Gene Therapy | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-010 |
| h-debate-f75956b4a67 | Lipid Co-factor Supplementation Therapy | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-010 |
| h-debate-2e6b77baccd | Cross-Seeding Autophagy Specificity Enhancement | 0.00 | 0.55 | SQSTM1 | proposed | 2026-04-29 | sda-2026-04-01-gap-011 |
| h-debate-ff417190bef | Glymphatic-Autophagy Coupling Enhancement | 0.00 | 0.55 | AQP4 | proposed | 2026-04-29 | sda-2026-04-01-gap-011 |
| h-debate-c0db7ae9bb4 | Stress Granule-Autophagy Interception Therapy | 0.00 | 0.55 | G3BP1 | proposed | 2026-04-29 | sda-2026-04-01-gap-011 |
| h-debate-b3b28c95ed6 | Lysosomal pH Microdomains Restoration | 0.00 | 0.55 | ATP6V1A | proposed | 2026-04-29 | sda-2026-04-01-gap-011 |
| h-debate-722e9da1535 | Lipid Raft Autophagy Receptor Reorganization | 0.00 | 0.55 | APOE | proposed | 2026-04-29 | sda-2026-04-01-gap-011 |
| h-debate-aff846dc0c3 | Retinal-Derived Neurotrophic Factor Delivery | 0.00 | 0.55 | BDNF, GDNF, TrkB, GFRα1 | proposed | 2026-04-29 | sda-2026-04-01-gap-012 |
| h-debate-9168ece51e3 | Voice-Guided Vagal Nerve Stimulation | 0.00 | 0.55 | CHAT, α7nAChR, TNF-α | proposed | 2026-04-29 | sda-2026-04-01-gap-012 |
| h-debate-27ffadf1dcb | Retinal Microvascular Neuroprotection | 0.00 | 0.55 | VEGFA, ANGPT2, CDH5 | proposed | 2026-04-29 | sda-2026-04-01-gap-012 |
| h-debate-d0b38913d62 | Smartphone-Detected Cognitive Load Modulation | 0.00 | 0.55 | COMT, CACNA1C, GRIN2B | proposed | 2026-04-29 | sda-2026-04-01-gap-012 |
| h-debate-c08c1a4f049 | Circadian-Speech Synchronization Therapy | 0.00 | 0.55 | CLOCK, BMAL1, MTNR1A/1B | proposed | 2026-04-29 | sda-2026-04-01-gap-012 |
| h-debate-84e1e96a9c5 | Gait-Motor Cortex Plasticity Enhancement | 0.00 | 0.55 | BDNF, CREB1, synapsin family genes | proposed | 2026-04-29 | sda-2026-04-01-gap-012 |
| h-debate-5dfaee2f11c | Circadian-Timed Senolytic Therapy | 0.00 | 0.55 | CLOCK, ARNTL, CDKN2A, CDKN1A | proposed | 2026-04-29 | sda-2026-04-01-gap-013 |
| h-debate-e7510405c8c | Extracellular Vesicle-Mediated SASP Disruption | 0.00 | 0.55 | IL1B, TNF, IL6, MIR146A | proposed | 2026-04-29 | sda-2026-04-01-gap-013 |
| h-debate-01b2d371572 | Astrocyte-Specific Senolytic Delivery via GFAP-Targeted Nanoparticles | 0.00 | 0.55 | GFAP, SRC, PIK3CA | proposed | 2026-04-29 | sda-2026-04-01-gap-013 |
| h-debate-510f995a6dc | Microglial Senescence Reversal Through TREM2 Agonism | 0.00 | 0.55 | TREM2, TYROBP, SYK | proposed | 2026-04-29 | sda-2026-04-01-gap-013 |
| h-debate-2d861158748 | Senolytic-Primed Autophagy Enhancement | 0.00 | 0.55 | MTOR, ULK1, BCL2L1 | proposed | 2026-04-29 | sda-2026-04-01-gap-013 |
| h-debate-e45b1cf8f2e | p21-Targeted Proteolysis-Targeting Chimeras (PROTACs) | 0.00 | 0.55 | CDKN1A | proposed | 2026-04-29 | sda-2026-04-01-gap-013 |
| h-debate-0d914b5bd78 | Dual BCL-2/CDK4/6 Inhibition for Enhanced Senolytic Efficacy | 0.00 | 0.55 | BCL2, CDK4, CDK6 | proposed | 2026-04-29 | sda-2026-04-01-gap-013 |
| h-debate-5810cce4cad | Mitochondrial SPM Synthesis Compartmentalization | 0.00 | 0.55 | ALOX15 | proposed | 2026-04-29 | sda-2026-04-01-gap-014 |
| h-debate-418a764b626 | Astrocyte-Microglial SPM Shuttle System Enhancement | 0.00 | 0.55 | ALOX15, GJA1 | proposed | 2026-04-29 | sda-2026-04-01-gap-014 |
| h-debate-3622e2b7533 | Blood-Brain Barrier SPM Transporter Upregulation | 0.00 | 0.55 | SLCO1A4, SLC27A1 | proposed | 2026-04-29 | sda-2026-04-01-gap-014 |
| h-debate-cb5a8619ae2 | Senescent Cell-Derived SPM Antagonist Neutralization | 0.00 | 0.55 | CDKN2A, TP53 | proposed | 2026-04-29 | sda-2026-04-01-gap-014 |
| h-debate-4e334c6b214 | Microglial SPM Receptor Priming Therapy | 0.00 | 0.55 | FPR2, GPR32, GPR18 | proposed | 2026-04-29 | sda-2026-04-01-gap-014 |